2nd Quarter - Amendment

ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY

Firm
Client
Income
—
Expenses
$608,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 20, 2009 $540,000 Replaced
2nd Quarter - Amendment (this page) Aug 6, 2009 $608,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Health care reform with respect to pharmacy issues and the professional role of pharmacists in health care reform; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation relating to health information technology and electronic prescribing.

LobbyistCovered position, as disclosed
MELISSA ANDEL —
RYAN DAY —
LAUREN LEA FULLER Chief Investigative Counsel, Sen. Finance Cmte.
WILLIAM HERMELIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Proposed changes to the Medicare Part D prescription drug benefit. Adjustments to Medicaid prescription drug reimbursement rates.

LobbyistCovered position, as disclosed
MELISSA ANDEL —
RYAN DAY —
LAUREN LEA FULLER Chief Investigative Counsel, Sen. Finance Cmte.
WILLIAM HERMELIN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Labor Issues/Antitrust/Workplace LBR

Legislation granting independent pharmacists collective bargaining rights.

LobbyistCovered position, as disclosed
MELISSA ANDEL —
RYAN DAY —
LAUREN LEA FULLER Chief Investigative Counsel, Sen. Finance Cmte.
WILLIAM HERMELIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

Health care reform with respect to pharmacy issues and the professional role of pharmacists in health care reform; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation relating to health information technology and electronic prescribing.

LobbyistCovered position, as disclosed
MELISSA ANDEL —
RYAN DAY —
LAUREN LEA FULLER Chief Investigative Counsel, Sen. Finance Cmte.
WILLIAM HERMELIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.